Clicky

Rubius Therapeutics, Inc.(RUBY)

Description: Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.


Keywords: Biotechnology Cancer Immunology Autoimmune Disease Application Software Rare Diseases Computer Aided Engineering Autoimmunity Therapies For Cancer Gout Red Blood Cell Computer Graphics Phenylketonuria Pku Therapeutic Applications Cystinuria Homocystinuria Enzyme Replacement Therapies Rtx

Home Page: www.rubiustx.com

RUBY Technical Analysis

399 Binney Street
Cambridge, MA 02139
United States
Phone: 617 679 9600


Officers

Name Title
Ms. Dannielle Appelhans CEO & Pres
Mr. Jose I. Carmona M.B.A. Principal Accounting Officer & Treasurer
Dr. Laurence A. Turka M.D. Chief Scientific Officer and Head of Research & Translational Medicine
Ms. Marissa Hanify Director of Corp. Communications

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4199
Price-to-Sales TTM: 0
IPO Date: 2018-07-18
Fiscal Year End: December
Full Time Employees: 9
Back to stocks